feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Oregon Ducks defense prevails

trending

Notre Dame dominates Syracuse

trending

Penn State beats Nebraska

trending

Boise State defeats Colorado State

trending

Utah defeats Kansas State

trending

Duke defeats UNC football

trending

Pitt defeats Georgia Tech football

trending

LAFC vs Vancouver semifinal

trending

Las Vegas Grand Prix 2025

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / India First: Teen AVM Treated with New Embolic Agent

India First: Teen AVM Treated with New Embolic Agent

21 Nov

•

Summary

  • A 16-year-old girl received a first-in-India treatment for AVM.
  • A minimally invasive technique used a new liquid embolic agent.
  • The procedure at Medanta Medicity successfully relieved severe symptoms.
India First: Teen AVM Treated with New Embolic Agent

A 16-year-old girl diagnosed with a rare congenital vascular disorder, arteriovenous malformation (AVM), has been successfully treated using a groundbreaking technique in Gurugram. This disorder, characterized by abnormal connections between arteries and veins, caused significant pain and swelling in the patient's right buttock.

The minimally invasive procedure, performed at Medanta Medicity, involved the use of ethylene-vinyl alcohol copolymer (EVOH), a liquid embolic agent typically reserved for complex neurovascular interventions. This marks the first time a peripheral EVOH embolic vial was employed in India for such a condition, offering a precise and controlled method to occlude the abnormal vessels.

The surgery, lasting two hours, effectively treated the AVM and relieved the young patient from symptoms including severe pain, swelling, skin changes, and fever. Doctors highlighted the success as a significant advancement in image-guided interventions for managing high-flow AVMs, especially in young patients where early recognition and treatment are crucial to prevent tissue damage and potentially life-threatening complications.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
AVM is a rare disorder where arteries connect directly to veins without capillaries. At Medanta, it was treated using a minimally invasive technique with an EVOH liquid embolic agent.
The EVOH agent allows slow, controlled delivery deep into the AVM's core, enabling occlusion in a single session, reducing complexity and recovery time compared to older methods.
The first use of a peripheral EVOH embolic vial for AVM treatment in India occurred at Medanta Medicity in Gurugram.

Read more news on

Healthside-arrow

You may also like

Gal Gadot's Life Saved by Doctors After Brain Clot

1 day ago • 7 reads

article image

Weight-Loss Drug Linked to Vision Loss: Compensation Awarded

21 Nov • 12 reads

NHS Offers New Hope for 1,500 Heart Patients

21 Nov • 17 reads

article image

PGIMER Concludes Stroke Awareness Program

20 Nov • 16 reads

article image

New Heart Failure Drug Shows Promise

19 Nov • 10 reads

article image